id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-350159-i2ig6dtr	Daunt, Anna	Validity of the UK Early Access to Medicines Scheme Criteria for Remdesivir use in patients with COVID-19 disease	2020-06-21		.txt	text/plain	981	56	57	3 An adapted version of the risk score, with twelve variables, was used to predict clinical deterioration (i.e. death or admission to critical care) in a cohort of 1,157 confirmed COVID-19 patients in one London NHS Trust. However, how the score proposed by EAMS performs in front-line settings and its implications for how many patients will likely receive Remdesivir for COVID-19 is currently unknown. According to the EAMS score, 262 (75.3%) of the eligible patients in our cohort would have been classified as high-risk and 86 (24.7%%) as low-risk. While reassuring that the scoring system seems show reasonable performance in identifying most of those at high risk of adverse outcomes in our cohort, 11.3% of those who deteriorate and met inclusion criteria were missed by this score. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study	./cache/cord-350159-i2ig6dtr.txt	./txt/cord-350159-i2ig6dtr.txt